FDA Finalizes Guidance On Early-Stage Clinical Trials
This article was originally published in The Gray Sheet
FDA released final guidance on granting investigational device exemptions for early feasibility medical device clinical studies Oct. 1. It grants manufacturers additional flexibility to change the clinical protocol in early feasibility trials, which are often conducted as the device’s design is still being finalized.
You may also be interested in...
4C Medical plans to conduct both an early feasibility study and the pivotal trial for its mitral regurgitation treatment device simultaneously in Japan, the US and Canada. The company says the study is the first early feasibility study in Japan for an implantable device.
While more early feasibility studies for devices are being conducted in the US in response to FDA reforms, small firms are still facing complications. Now a draft blueprint from the public-private Medical Device Innovation Consortium seeks to make the process more straightforward.
According to the latest numbers, CDRH says it has reduced median investigational review exemption review times to 30 days, and three out of four IDEs are now fully approved after two review cycles.